Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scholar Rock HoldingFRA:2QK +0.49%28 5-Year Yield-on-Cost % is 0.00 as of Jul. 30, 2026. GuruFocus rates FRA:2QK with a GF Score™ of 28/100. The stock has 4 warning signs investors should review. Among 150 Biotechnology companies, Scholar Rock Holding ranks worse than 666666% on this metric.
Scholar Rock Holding's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Scholar Rock Holding's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:2QK's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.695 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Scholar Rock Holding (FRA:2QK) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Scholar Rock Holding 5-Year Yield-on-Cost % Related Terms
FRA:2QK vs DFTX, DNTH, ORKA: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Scholar Rock Holding's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's 5-Year Yield-on-Cost % falls into.
Scholar Rock Holding 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Scholar Rock Holding (FRA:2QK) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 30, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Scholar Rock Holding and its competitors. According to the industry distribution chart, Scholar Rock Holding ranks #999999 out of 150 companies in the Biotechnology industry.
Is Scholar Rock Holding's 5-Year Yield-on-Cost % too high?
Scholar Rock Holding's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Scholar Rock Holding ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scholar Rock Holding has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's 5-Year Yield-on-Cost % compare to DFTX and DNTH?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Scholar Rock Holding in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Scholar Rock Holding and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scholar Rock Holding's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Scholar Rock Holding's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
28GF Score
Get the complete analysis for FRA:2QK
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
